Acute Intermittent Porphyria Market Report 2024

This Acute Intermittent Porphyria market report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.

The acute intermittent porphyria market size has grown strongly in recent years. It will grow from $4.11 billion in 2023 to $4.37 billion in 2024 at a compound annual growth rate (CAGR) of 6.2%. The growth observed in the historic period can be attributed to factors such as increased healthcare expenditure, expansion in the biopharmaceuticals market, a rising prevalence of genetic disorders, the growth of telemedicine services, and a heightened focus on early detection.

The acute intermittent porphyria market size is expected to see strong growth in the next few years. It will grow to $5.61 billion in 2028 at a compound annual growth rate (CAGR) of 6.4%. The anticipated growth during the forecast period can be attributed to factors such as the increasing incidence of acute intermittent porphyria, growing awareness of rare diseases, supportive government policies, heightened patient advocacy, and the expansion of genetic testing services. Key trends for this period include advancements in diagnostic techniques, the development of novel therapeutic options, increased investment in research and development, collaborations between pharmaceutical companies, and technological innovations in treatment.

The increasing prevalence of metabolic disorders is expected to drive growth in the acute intermittent porphyria (AIP) market. Metabolic disorders are conditions caused by abnormal chemical reactions in the body that disrupt normal metabolism. Factors such as genetic predispositions, lifestyle choices, environmental influences, and heightened awareness and diagnosis contribute to the rise in these disorders. This increase is prompting the pharmaceutical industry to invest in treatments for rare and genetic conditions, including acute intermittent porphyria. For example, the Cleveland Clinic reported in December 2023 that inherited metabolic disorders affect approximately 1 in 1,000 to 2,500 births globally, highlighting the growing need for targeted treatments like those for AIP.

Leading companies in the AIP market are focusing on developing advanced products, such as management tablets, to improve patient care. These tablets are designed to manage or prevent symptoms and acute attacks associated with AIP. In October 2023, Alembic Pharmaceuticals Ltd., based in India, received US Food & Drug Administration (USFDA) approval for its Chlorpromazine Hydrochloride Tablets USP, available in various doses (10 mg, 25 mg, 50 mg, 100 mg, and 200 mg). These tablets are used to manage symptoms of psychotic disorders, control nausea and vomiting, and provide relief from other conditions, including acute intermittent porphyria.

In April 2024, the American Porphyria Foundation (APF), a US-based non-profit organization, collaborated with Recordati Rare Diseases. This partnership aims to raise awareness about porphyria and enhance public support and understanding of AIP. Recordati Rare Diseases, an Italy-based, involved in the treatment of acute intermittent porphyria.

Major companies operating in the acute intermittent porphyria market are Pfizer Inc., Johnson & Johnson, Roche Holding AG, Merck & Co. Inc., AbbVie Inc., Sanofi SA, AstraZeneca Plc, Novartis AG, GlaxoSmithKline Plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Novo Nordisk A/S, Regeneron Pharmaceuticals Inc., Daiichi Sankyo Company Limited, Vertex Pharmaceuticals Inc., Eisai Co. Ltd., Octapharma AG, BioMarin Pharmaceutical Inc., Swedish Orphan Biovitrum AB, Alnylam Pharmaceuticals Inc., Mylan N.V., Clinuvel Pharmaceuticals Ltd., Recordati Rare Diseases Inc.

North America was the largest region in the acute intermittent porphyria market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the acute intermittent porphyria market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the acute intermittent porphyria market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Acute intermittent porphyria (AIP) is a rare genetic disorder affecting the production of heme, an essential component of hemoglobin in the blood. It is characterized by intermittent episodes of severe abdominal pain, gastrointestinal issues, and neurological symptoms such as muscle weakness, seizures, and mental disturbances including anxiety, confusion, or hallucinations.

Diagnosing acute intermittent porphyria typically involves urine tests, blood tests, serum tests, DNA tests, and others. Urine tests analyze a sample to detect elevated levels of porphyrins or their precursors, which indicate AIP. Treatment options include prophylactic hematin infusions, gonadotropin-releasing hormone analogues, and others. These diagnostic and treatment approaches are utilized by hospitals, clinics, ambulatory surgical centers, and research centers.

The acute intermittent porphyria market research report is one of a series of new reports that provides acute intermittent porphyria market statistics, including acute intermittent porphyria industry global market size, regional shares, competitors with a acute intermittent porphyria market share, detailed acute intermittent porphyria market segments, market trends and opportunities, and any further data you may need to thrive in the acute intermittent porphyria industry. This acute intermittent porphyria market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The acute intermittent porphyria market consists of revenues earned by entities by providing services such as genetic testing, clinical consultation, treatment planning and medication management. The market value includes the value of related goods sold by the service provider or included within the service offering. The acute intermittent porphyria market also includes sales of symptom management products, medical devices, nutritional supplements and emergency kits. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.